Results 171 to 180 of about 227,662 (304)

Small Strokes, Big Impact: Excessive Mortality After Acute Ischemic Stroke in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Acute ischemic stroke (AIS) in those with Parkinson's disease (PD) is a growing healthcare burden but mortality studies are significantly lacking. Objective To map short‐ and long‐term survival, stratified by relevant comorbidities and stroke characteristics.
Lee E. Neilson, Chen Lin, Anusha Mishra, Gregory D. Scott   +3 more
wiley   +1 more source

Sex Differences in Statin Intolerance: Insights From the CLEAR Outcomes Trial. [PDF]

Clin Cardiol
Naderi S, Brennan D, Li N, Lincoff AM, Nicholls SJ, Nissen SE, Plutzky J, Powell HA, Robinson P, Cho L.   +9 more
europepmc   +1 more source

Elevation of Stearoyl‐Coenzyme A Desaturase and Monounsaturated Fatty Acids in Parkinson's Disease Serum

Movement Disorders, EarlyView.
Abstract Background Emerging evidence indicates that dysregulation of monounsaturated fatty acids (MUFAs), synthesized by the enzyme stearoyl‐coenzyme A desaturase (SCD), impacts on α‐synuclein pathology in the Parkinson's disease (PD) brain. Objective The objective of this study was to analyze SCD and MUFA‐enriched lipids in the periphery of patients ...
Finula I. Isik, Russell Pickford, Michelle Chua, Simon J.G. Lewis, Nicolas Dzamko, Woojin Scott Kim   +5 more
wiley   +1 more source

Statins and postmenopausal breast cancer risk; results from the KARMA cohort. [PDF]

Cancer Causes Control
Klintman M, Rosendahl AH, Johannesen BR, Cronin-Fenton D, Eriksson M, Czene K, Hall P, Borgquist S.   +7 more
europepmc   +1 more source

Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort

Movement Disorders, EarlyView.
Abstract Background Previous studies on calcium channel blockers (CCBs) and Parkinson's disease (PD) risk reached conflicting conclusions. Objectives We examined the relationship between CCBs and PD in the E3N cohort of French women followed for 15 years (2004–2018), while taking into account the potential for reverse causation.
Emilie Moutard, Agnès Fournier, Émeline Courtois, Fanny Artaud, Pascale Tubert‐Bitter, Emmanuel Roze, Ismaïl Ahmed, Anne C.M. Thiébaut, Alexis Elbaz, Thi Thu Ha Nguyen   +9 more
wiley   +1 more source

Statin prescription rates for prevention of atherosclerotic cardiovascular disease in adults 40-75 years old with type 1 diabetes. [PDF]

BMJ Open
Lundholm MD.
europepmc   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Association Between Statin Use and Non-Melanoma Skin Cancer Risk: A Distributed Network Analysis of 11 Real-World Databases. [PDF]

Ann Dermatol
An J, Kim MS, Lee Y, Lew BL, Kwon SH.
europepmc   +1 more source

Cardiovascular Disease and Obesity Medications in Older Women by Obesity‐Related Cancers Status: SEER‐Medicare 2007–2015

Obesity, EarlyView.
ABSTRACT Objective This study evaluated the association between antiobesity medications (AOM) and incident cardiovascular disease (CVD) among older women, examining this relationship within and across survivors of obesity‐related cancers (ORCa) and age‐matched cancer‐free populations.
David S. Lopez, Omer Abdelgadir, Yuanyi Zhang, Jesús Gibran Hernández‐Pérez, Maryam R. Hussain, Mohanad Albayyaa, Rasmi Nair, Yong‐Fang Kuo, Jaime P. Almandoz, Lindsay G. Cowell, Sarah E. Messiah   +10 more
wiley   +1 more source

Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity. [PDF]

Inflamm Regen
Alabrahim OAA, Allam NK.
europepmc   +1 more source